刘畅敏, 郑翊轩, 于景盛, 王晖, 陈士林, 宋驰. 基于肠道微生物与G蛋白偶联受体互作关系探讨中药有效成分筛选新模式J. 药学学报, 2024, 59(11): 3042-3056. DOI: 10.16438/j.0513-4870.2024-0333
引用本文: 刘畅敏, 郑翊轩, 于景盛, 王晖, 陈士林, 宋驰. 基于肠道微生物与G蛋白偶联受体互作关系探讨中药有效成分筛选新模式J. 药学学报, 2024, 59(11): 3042-3056. DOI: 10.16438/j.0513-4870.2024-0333
LIU Chang-min, ZHENG Yi-xuan, YU Jing-sheng, WANG Hui, CHEN Shi-lin, SONG Chi. A new model for screening active ingredients in traditional Chinese medicine based on the interactions between gut microorganisms and G protein-coupled receptorJ. Acta Pharmaceutica Sinica, 2024, 59(11): 3042-3056. DOI: 10.16438/j.0513-4870.2024-0333
Citation: LIU Chang-min, ZHENG Yi-xuan, YU Jing-sheng, WANG Hui, CHEN Shi-lin, SONG Chi. A new model for screening active ingredients in traditional Chinese medicine based on the interactions between gut microorganisms and G protein-coupled receptorJ. Acta Pharmaceutica Sinica, 2024, 59(11): 3042-3056. DOI: 10.16438/j.0513-4870.2024-0333

基于肠道微生物与G蛋白偶联受体互作关系探讨中药有效成分筛选新模式

A new model for screening active ingredients in traditional Chinese medicine based on the interactions between gut microorganisms and G protein-coupled receptor

  • 摘要: 肠道微生物及其代谢物与人类疾病密切相关, 其通过与受体互作而影响疾病的发生发展。G蛋白偶联受体(G protein-coupled receptor, GPCR) 是一类存在于细胞膜表面的受体超家族, 该受体家族广泛参与人体生理活动, 被认为是重要的药物靶点。中药具有多成分、多靶点、多通路的特点。越来越多的研究表明中药可通过调节肠道微生物及其代谢物而影响GPCR调控模式, 最终干预疾病。本文综述了肠道微生物与人类疾病的现状、肠道微生物及其代谢物与GPCR互作关系、GPCR药物开发现状。基于上述研究, 本文提出“中药-肠道功能菌群单元-GPCR-疾病”研究新模式。运用多组学技术阐释中药有效成分、肠道功能菌群单元及GPCR三者之间互作关系及其对疾病的影响。本文将为解析中药药效物质基础, 寻找中药作用新靶标提供新思路。

     

    Abstract: Gut microbiome and their metabolites are closely related to human diseases, which influence the development of diseases by interacting with receptors. G protein-coupled receptor (GPCR) is a receptor superfamily that exists on the surface of cell membrane, which is involved in a wide range of human physiological activities. GPCR is currently considered as important drug targets. Traditional Chinese medicines (TCM) are characterized by multi-components, multi-targets, and multi-pathways. More and more studies have demonstrated that TCM can ultimately intervene in diseases by modulating gut microbiome and their metabolites, affecting their interactions with GPCR. This review discusses the status of gut microbiome and human diseases, the interactions of gut microbiome and their metabolites with GPCR, and the status of GPCR drug development. Based on the above contents, a new model of "TCM-gut microbiome panel-GPCR-disease" is proposed. The interactions between active ingredients of TCM, gut microbiome panel, and GPCR and their effects on disease are elucidated through multi-omics techniques. This review will provide new ideas for analyzing the pharmacological mechanism of TCM efficacy and searching for new targets of TCM.

     

/

返回文章
返回